XDXiao Ding

Xiao Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiao Ding has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global, regional and national burden of neurodegenerative diseases attributable to smoking: A descriptive study based on the Global Burden of Disease Study 2021

    by Zeyu Yang, Zhaoyi Jing, Qingyu Song, Xiao Ding, Xiaohui Lu

    Introduction: Neurodegenerative diseases impose a significant healthcare burden worldwide. Within the context of smoking, the risk of dementia and multiple sclerosis significantly increases. However, the global epidemiological characteristics of smoking-induced neurodegenerative diseases remain...

  • Open Access

    Genetically predicted the causal relationship between blood metal levels and ischemic stroke risk based on Asian ethnicity

    by Zhaoyi Jing, Bingbing Wang, Wenzhu Hao, Xiao Ding

    Metal element supplementation leads to elevated concentrations of these minerals in the blood. Therefore, any association between blood metal levels and the risk of ischemic stroke is potentially of great public health significance. The results of many observational studies suggest a correlation between blood metal levels and ischemic stroke. However, observational study is influenced by confounding factors. Moreover, there were comparatively few studies on Asian populations. In this study, we aimed to investigate the causal relationship between blood metal levels and risk of ischemic stroke based on Asian ethnicity. We applied 2-sample Mendelian randomization to estimate the causal effects of 42 blood metal levels on ischemic stroke risk. We conducted scrutiny on the SNPs using the LDtrait online tool. A series of sensitivity analyses were conducted to examine the heterogeneity and pleiotropy of the results. We found that plasma calcium levels (β = 0.038, se = 0.016, P = .019) was a risk factor. Conversely, plasma chromium levels (β = −0.031, se = 0.015, P = .036) were shown to act as a protective factor for ischemic stroke. These findings were consistent across different sensitivity analyses. This research offers proof indicating a causal link between plasma concentrations of elemental calcium and chromium and an elevated risk of ischemic stroke among Asians. This highlights the significance of keeping track of blood metal concentrations as a possible preventive and intervention measure for ischemic stroke. Additional studies are necessary to confirm these results and investigate the biological mechanisms involved.

  • Realgar bioleaching solution suppress ras excessive activation by increasing ROS in Caenorhabditis elegans

    by De Juan Zhi, Na Feng, Dong Ling Liu, Rong Li Hou, Mei Zu Wang, Xiao Xia Ding, Hong Yu Li

    Although realgar bioleaching solution (RBS) has been proved to be a potential candidate for cancer therapy, the mechanisms of RBS anticancer are still far from being completely understood. Dosed with RBS in C. elegans, the multivulva phenotype resulting from oncogenic ras gain-of-function was inhibited in a dose dependent manner. It could be abrogated by concurrent treatment C. elegans with RBS and the radical scavenger DMSO. However, RBS could not induce DAF-16 nuclear translocation in TJ356 or the increase of HSP 16.2 expression in CL2070, which both could be aroused visible GFP fluorescent variation to represent for oxidative stress generation. Treatment C. elegans with superoxide anion generator paraquat, similar results were also obtained. Our results indicated that RBS suppress excessive activated ras by increasing reactive oxygen species (ROS) in C. elegans. Secondly, ROS induced by RBS significantly accumulated on a higher level in C. elegans with a mutational ras than that with wild ras, thus leading to oxidative stress on ras gain-of-function background rather than on normal ras context. Our results firstly demonstrated that using C. elegans as a model organism for evaluating prooxidant drug candidates for cancer therapy.